Strongbridge Biopharma plc
If you purchased Strongbridge Biopharma plc securities and would like to join the action, please click "Join This Action" below.
STRONGBRIDGE BIOPHARMA MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF STRONGBRIDGE BIOPHARMA PLC IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – SBBP
May 24, 2021.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Strongbridge Biopharma plc (NASDAQ: SBBP) to Xeris Pharmaceuticals, Inc. is fair to Strongbridge shareholders. Under the terms of the merger, Strongbridge shareholders will receive 0.7840 shares of the combined company and 1 contingent value right (“CVR”) for each Strongbridge share that they own. The CVR is worth up to $1.00 in cash or stock of the combined company upon achievement of certain triggering events.
The investigation concerns whether Strongbridge and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Strongbridge shareholders; (2) determine whether Xeris is underpaying for Strongbridge; and (3) disclose all material information necessary for Strongbridge shareholders to adequately assess and value the merger consideration. On behalf of Strongbridge shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.